Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The company's pipeline focuses on two lead product candidates: budoprutug, an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, and CLYM116, a next-generation anti-APRIL monoclonal antibody. Budoprutug is being developed for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with clinical trials ongoing in the United States, Australia, and China. CLYM116 is being evaluated for IgA nephropathy, with Phase 1 trials initiated in Australia and a Phase 1/2 trial underway in China in partnership with Mabworks. The company holds worldwide rights to budoprutug for non-oncology indications and rights to CLYM116 outside of Greater China.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ir.climbbio.com
Sector Healthcare IR page ir.climbbio.com
Tags
immune-mediated diseases, monoclonal antibodies, b-cell depletion, nephrology, rheumatology, hematology, clinical-stage, autoimmune disorders, budoprutug, CLYM116, Mabworks
Press page —

Metrics

Valuation  
Market cap $ 662.142M
Market cap (USD) $ 662.142M
P/E -14.16
PEG —
P/BV 2.90
P/S —
P/OCF -12.60
P/FCF -12.14
Dividend yield —
Turnover / mcap —
Returns  
ROE -32.1%
ROI -47.9%
ROIC -40.7%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score -58.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 167.744M 217.187M 110.469M 134.992M 173.241M 24.631M
Net profit -59.851M -73.897M -35.119M -45.244M -47.48M -20.668M
Free cash flow -54.542M -20.207M -20.599M -37.369M -36.072M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 4 1.8 2.7 3.67 10.46 —
Price performance 12m 1.22 -0.33 -0.26 -0.65 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 900,000 480,000 349,000 532,000 541,000
Cash and deposits (USD) 21.2M 20.5M 46.9M 43.6M 93.1M 87.2M 35.7M
Right-of-use assets (USD) — — 0.00 471,000 199,000 490,000 505,000
Cash flow detail
Operating cash flow (USD) — -14.1M -36.1M -37.4M -20.6M -15.6M -54.4M
Purchases of property, plant and equipment (USD) — — — — 0.00 -4.65M -186,000
Change in payables (cash effect) (USD) — -167,000 318,000 -653,000 -686,000 -963,000 1.56M
Share-based compensation (USD) — 707,000 3.74M 6.99M 12.8M 5.56M 8.05M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — -20.6M -20.2M -54.5M
Income detail
Research and development expense (USD) — 8.77M 22M 26.2M 15.4M 14.2M 46.7M
↳ 5y CAGR +39.7%
Total comprehensive income (USD) — — -47.6M -45.5M -34.8M -73.9M -59.4M
Comprehensive income to owners (USD) — — -47.6M -45.5M -34.8M -73.9M -59.4M
Reported Sep 13, 2021 Mar 7, 2022 Mar 6, 2023 Mar 6, 2023 Mar 25, 2025 Mar 25, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing

Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN; initial data expected in the first half of 2027

Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027

Initial budoprutug Phase 1b data in SLE demonstrated a favorable safety and tolerability profile and dose-dependent B-cell depletion; additional Phase 1b data in ITP at American Society of Hematology in December 2026

$227.6 million in cash, cash equivalents and marketable securities as of September 30, 2026; expected cash runway into the second half of 2028

WELLESLEY HILLS, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

October 24, 2026

PDF Version

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027

200 mg and 600 mg doses have been generally well-tolerated

Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation

WELLESLEY HILLS, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced new clinical data for budoprutug, its anti-CD19 monoclonal antibody (mAb), in two immune-mediated renal diseases, primary membranous nephropathy (pMN) and minimal change disease (MCD). These data were presented at the American Society of Nephrology (ASN) Kidney Week 2026, which is taking place October 21-25, 2026, in Denver, Colorado.

PrisMN is an ongoing Phase 2 dose-escalation trial evaluating budoprutug at three dose levels (200 mg, 600 mg, and 1000 mg) in patients with moderate to severe pMN. Patients enrolled in the reported cohorts were treatment-experienced, with high proteinuria and elevated PLA2R antibody levels at baseline. At Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission. Initial data from the ongoing 600 mg cohort suggest greater drug exposure and deeper peripheral B-cell depletion compared with 200 mg. Budoprutug has been generally well tolerated in both cohorts to date, with follow-up through Week 12 for 200 mg and Week 6 for 600 mg. Enrollment is ongoing in the 1000 mg cohort.

In a separate case study presented yesterday, one patient with frequently relapsing MCD received 100 mg of budoprutug. The patient experienced three-year steroid-free remission and remained in remission for one year following B-cell reconstitution. This observation supports further investigation of budoprutug in MCD.

"Current treatment strategies fail to induce complete remission in most patients with pMN, underscoring the need for more effective treatments,” said Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center. “While complete remission often takes more than a year to achieve, changes in PLA2R antibody levels can be appreciated much earlier in the treatment course and serve as an early indicator of therapeutic efficacy. Reductions in PLA2R antibody levels have been shown to correlate with downstream improvements in proteinuria, and ultimately complete remission. In the PrisMN study, the low-dose budoprutug cohort demonstrated encouraging PLA2R antibody reductions and immunologic remission rates in patients with moderate to severe pMN. These early results are highly promising, and I look forward to seeing how these data evolve as follow-up continues and higher-dose cohorts read out. These data provide further evidence that targeting CD19 with budoprutug may be a compelling approach in the treatment of pMN."

“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses,” said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. “The observed pharmacokinetics confirm that patients with pMN have increased clearance of budoprutug compared to patients who do not have proteinuria. We are encouraged by the greater exposure and deeper B-cell depletion we are seeing at these early time points in the 600 mg cohort. As enrollment and follow-up continue, we look forward to sharing additional data. Beyond pMN, we are encouraged by the sustained steroid-free remission reported in the MCD case, supporting further investigation of budoprutug in additional glomerular diseases and highlighting its potential impact across different B-cell mediated diseases.”

Key highlights from the oral presentation:

  • Early immunologic activity at 200 mg

  • Mean PLA2R antibody reduction of 70% at Week 12; five of 13 patients (38%) achieved immunologic remission. Mean reduction of 80% at Week 12 for patients with baseline PLA2R antibody (Ab) <175 RU/mL

  • Phase 2 Week 12 data consistent with Phase 1b Week 12 data across B-cell depletion, anti-PLA2R antibody reduction, and immunologic remission rate

  • Population PK analysis and emerging 600 mg data support the evaluation of higher doses

  • Population PK analysis completed across all budoprutug studies (n≈120) found that patients with high proteinuria (median UPCR of 6.8 g/g) clear budoprutug ≥2-fold faster than non-proteinuric individuals, supporting the use of higher doses in pMN

  • Mean peripheral CD20+ B-cell suppression at Week 4 was 98% at 600 mg, compared with 74% at 200 mg

  • Safety and tolerability

  • Budoprutug was generally well tolerated in the 200 mg and 600 mg cohorts

  • Most adverse events were mild to moderate (Grade 1 or 2), with no treatment-related serious adverse events, adverse events leading to treatment discontinuation, or deaths reported

Following the oral presentation at 5:30 p.m. MT., the presentation and poster will be available on the Pipeline & Science—Publications page of the Company’s website here.

About Primary Membranous Nephropathy (pMN) Primary membranous nephropathy is an autoantibody mediated disease characterized by proteinuria, nephrotic syndrome, and progressive loss of renal function. Patients with uncontrolled disease may develop chronic kidney disease or end-stage kidney disease, requiring dialysis or transplantation. There are about 75,000 people in the U.S. living with pMN. Currently, there are no FDA approved therapies for pMN.

About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.

About Budoprutug Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.

Forward-Looking Statements This press release contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; the anticipated timelines for enrolling patients in planned clinical trials; and other statements containing the words “anticipate,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “suggest,” “target,” “will” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Mabworks; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulations; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.

Investors and Media Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected]

October 23, 2026

PDF Version

90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval

~70% reduction in Gd-IgA1 at 12 weeks

~33-day half-life

NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027

Global Phase 3 trial expected to initiate in 2027

WELLESLEY HILLS, Mass. and BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), today announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody (mAb), in development for IgA nephropathy (IgAN). These data were presented at the American Society of Nephrology (ASN) Kidney Week 2026, which is taking place October 21-25, 2026, in Denver, Colorado.

CLYM116/MIL116 is being evaluated in complementary Phase 1 trials in Australia and China. Both are randomized, double-blind, placebo-controlled, ascending-dose studies designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) CLYM116/MIL116 in healthy volunteers and enrolled 46 and 42 participants respectively.

Near-complete free APRIL suppression was sustained through 12 weeks following a single SC dose ≥480 mg. Following a single 800 mg dose, ~70% reduction in Gd-IgA1 and ~60% reduction in IgA were observed at 12 weeks. PK was consistent across both studies. Exposure was linear, with no target-mediated drug disposition (TMDD) observed across the effective dose range. Together, these PK and PD data support an every 12-week (Q12W) dosing regimen. CLYM116/MIL116 has been generally well tolerated, with no dose limiting toxicities, treatment-related serious adverse events (SAEs), or hypogammaglobulinemia. The NAVIGATE-2 Phase 2 trial is currently enrolling IgAN patients to confirm the Q12W dosing regimen, and a global Phase 3 trial is expected to initiate in 2027, pending regulatory feedback.

“What excites us most about these two datasets is that they offer complementary validation of what we view as a best-in-class anti-APRIL profile for IgA nephropathy,” said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. “CLYM116 was engineered as a sweeper antibody, and we’ve now seen this mechanism translate into superior in vivo potency, extended half-life, and predictable, linear exposure across two, parallel clinical studies. This differentiated pharmacokinetic profile drives deep and durable APRIL suppression, leading to substantial reductions in IgA and Gd-IgA1, a key pathogenic driver of IgAN. Our ability to rapidly generate this body of evidence reflects the strength of our partnership with Mabworks and allows us to accelerate this potentially transformative program into later-stage development.”

“We are encouraged by the consistency of the findings across both studies, and we continue to move with urgency to generate data in patients,” said Feng Li, Ph.D., Chairman of the Board, Chief Executive Officer and General Manager of Mabworks. “IgA nephropathy affects patients worldwide, carrying a particularly high burden in patients of Asian descent. Clinicians and patients have responded with real enthusiasm to the prospect of a highly effective anti-APRIL therapy with an extended dosing interval, and that enthusiasm has translated into strong enrollment momentum in the NAVIGATE-2 trial. Patient data from this ongoing study will allow us to confirm our target Q12W dosing interval and move a single dosing regimen into Phase 3. Together with Climb Bio, we are planning a global registrational study designed to bring MIL116 to patients across geographies as efficiently as possible.”

Key Highlights from the CLYM116/MIL116 presentations:

  • Long half-life:~33-day half-life estimated based on 800 mg and 320 mg MAD, 3.5x that reported for sibeprenlimab

  • Predictable PK: linear clearance across the effective dose range, with no TMDD at doses ≥160 mg, consistent with the sweeper-mediated degradation of APRIL

  • Robust and durable APRIL suppression: ≥90% free APRIL suppression through the full 12-week dosing interval following a single SC injection at dose levels ≥480 mg

  • **Significant Gd-IgA1 and IgA suppression: ~**70% reduction in Gd-IgA1 and ~60% reduction in IgA at 12 weeks, following a single SC injection of 800 mg, the selected loading dose for the NAVIGATE-2 Phase 2 trial

  • **Q12W dosing regimen:**PK/PD modeling supports sustained APRIL suppression with Q12W dosing, now being evaluated in patients with IgAN in the NAVIGATE-2 Phase 2 trial

  • **Favorable safety and tolerability profile:**Generally well tolerated across all dose levels evaluated (25 mg to 1280 mg) with no dose-limiting toxicities, treatment-related SAEs, or hypogammaglobulinemia

  • Injection site reactions were infrequent, occurring in 5 of 88 participants across both studies; all five were Grade 1 and resolved without intervention

  • Partnership supports accelerated development: NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in the first half of 2027; a global Phase 3 trial is anticipated to initiate in 2027, pending regulatory feedback

About IgA Nephropathy (IgAN) IgA nephropathy (IgAN) is a progressive autoimmune kidney disease characterized by proteinuria, hematuria, and loss of kidney function. Immune complexes formed by abnormal, galactose-deficient IgA1 (Gd-IgA1) and the autoantibodies that target Gd-IgA1 deposit in the glomeruli, causing inflammation and scarring that can lead to chronic kidney disease and kidney failure. IgAN is the most common primary glomerulonephritis worldwide, is often diagnosed in young adults, and approximately 200,000 people in the U.S. live with the disease. While recently approved therapies have expanded treatment options, a significant unmet need remains for treatments that address the underlying cause of disease by reducing the production of abnormal pathogenic IgA and associated autoantibodies.

About CLYM116/MIL116 CLYM116/MIL116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B-cell activity in autoimmune diseases. CLYM116/MIL116 employs a novel pH-dependent bind-and-release ‘sweeper’ mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing. CLYM116/MIL116 is being advanced for the treatment of IgA nephropathy (IgAN) and may also have broader utility across other B-cell mediated diseases where APRIL plays a critical role. Climb Bio retains worldwide rights to CLYM116/MIL116 outside of Greater China; Mabworks retains rights in Greater China.

About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.

About Beijing Mabworks Biotech Co., Ltd. Beijing Mabworks Biotechnology Co., Ltd. focuses on the research, development, and industrialization of innovative antibody-targeted therapeutics, and is committed to bringing innovative treatment options to patients with autoimmune diseases and cancer. The Company translates scientific breakthroughs in immunology and biology into novel antibody-targeted therapies, pursuing product development and technological innovation across various autoimmune disease and oncology markets with substantial unmet medical needs and market potential. The Company is a National High-tech Enterprise, a Beijing “Specialized, Refined, Distinctive and Innovative” SME, and hosts a Beijing Key Laboratory and a Beijing Engineering Laboratory, as well as an enterprise postdoctoral research workstation and an academician expert workstation.

Forward-Looking Statements This press release contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of CLYM116; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; the anticipated timelines for enrolling patients in planned clinical trials; the anticipated benefits of Climb Bio’s technology transfer and exclusive license agreement with Mabworks; and other statements containing the words “anticipate,” “continue,” “expect,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “will,” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Mabworks; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.

Investors and Media Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected]

Prompts

Climb Bio, Inc. (ticker CLYM), listed in United States.

Company History

Date Change Detail
Oct 2, 2024 Renamed ELIEM THERAPEUTICS, INC. → CLIMB BIO, INC.
— Former tickers ELYM

ETFs Holding Climb Bio, Inc.

ETF Weight in ETF Shares Market value As of
VAMO 0.84% 76,753 $ 913.361K Jul 31, 2026
FMED 0.38% 14,400 $ 197.712K Aug 31, 2026
AFSM 0.34% 49,904 $ 496.046K Nov 16, 2026
VFMO 0.18% 246,832 $ 3.389M Aug 31, 2026
FFSM 0.11% 133,441 $ 1.588M Jul 31, 2026
RESM 0.02% 57 $ 743.28 Jun 30, 2026
AVSC 0.02% 79,461 $ 789.842K Nov 16, 2026
DFAS 0.01% 177,010 $ 1.924M Nov 12, 2026
FSEG 0.00% 20 $ 260.80 Jun 30, 2026
DCOR 0.00% 69,137 $ 751.519K Nov 12, 2026
DFAC 0.00% 66,861 $ 726.779K Nov 12, 2026
DFAU 0.00% 9,346 $ 101.591K Nov 12, 2026
DFUS 0.00% 6,647 $ 72.253K Nov 12, 2026
DFSU 0.00% 646 $ 7,022.02 Nov 12, 2026